- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
NuLife Shares Plan to Commercialize Lead Compound in Ecuador
NuLife Sciences through is subsidiary announced their plan to commercialize their lead compound lyophilized Cytokine Concentrated Plasma in Ecuador.
NuLife Sciences (OTCQB:NULF) through is subsidiary announced their plan to commercialize their lead compound lyophilized Cytokine Concentrated Plasma in Ecuador.
As quoted in the press release:
The lyoCCP product is produced utilizing the NuLife Technique, the proprietary platform being developed by NuLife Sciences. The proprietary product has shown impressive results in aiding the healing of wounds that have been resistant to closure with traditional methods. An observational study was conducted earlier this year, showing impressive results in ten subjects. A larger study is planned in the coming weeks and months.
The worldwide wound care market is expected to be in excess of $20 billion by 2022. In fact, the worldwide incidence of all types of wounds ranges between 2% and 6%. These wounds represent a significant health risk, negatively impacting the quality of life for patients. In addition, they are very costly to healthcare systems.
“We are pleased with the study results and look forward to making an impact on the wound care market with our lyoCCP product,” said John Hollister, NuLife Sciences Chief Executive Officer.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â